ConductScience.org, home

Paper19917871

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Azzoli CG and 19 others. J Clin Oncol, 2009. Cited by 619 papers, by iCite.

Cite this record

ConductScience Library. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Papers, record 19917871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19917871

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2009
PubMed
Publication types
Journal Article, Practice Guideline
PubMed
Citations, by iCite
619
iCite
Relative citation ratio, by iCite
15.1
iCite
Revised in PubMed
2026-05-26
PubMed

Authors20

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Azzoli CGChristopher G
2Baker S JrSherman
3Temin SSarah
4Pao WWilliam
5Aliff TTimothy
6Brahmer JJulie
7Johnson DHDavid H
8Laskin JLJanessa L
9Masters GGregory
10Milton DDaniel
11Nordquist LLuke
12Pfister DGDavid G
13Piantadosi SSteven
14Schiller JHJoan H
15Smith RReily
16Smith TJThomas J
17Strawn JRJohn R
18Trent DDavid
19Giaccone GGiuseppe
20American Society of Clinical OncologyGroup

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans
Neoplasm Staging

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03976518Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)Background

Source ClinicalTrials.gov

Download CSV of trials

References151

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118283036A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.Ann Oncol2008https://conductscience.org/library/papers/18283036PubMed
218316562
Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study.
Clin Cancer Res2008https://conductscience.org/library/papers/18316562PubMed
317720276
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Lung Cancer2008https://conductscience.org/library/papers/17720276PubMed
415741570Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst2005https://conductscience.org/library/papers/15741570PubMed
515728228Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.J Clin Oncol2005https://conductscience.org/library/papers/15728228PubMed
618809811Missed opportunities for interval empathy in lung cancer communication.Arch Intern Med2008https://conductscience.org/library/papers/18809811PubMed
717047648A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.Br J Cancer2006https://conductscience.org/library/papers/17047648PubMed
816014882Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med2005https://conductscience.org/library/papers/16014882PubMed
918375902Physician-identified factors affecting patient participation in reaching treatment decisions.J Clin Oncol2008https://conductscience.org/library/papers/18375902PubMed
1019692680Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med2009https://conductscience.org/library/papers/19692680PubMed
1115447984Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.Clin Cancer Res2004https://conductscience.org/library/papers/15447984PubMed
1217602080Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.J Clin Oncol2007https://conductscience.org/library/papers/17602080PubMed
1317762336The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.J Thorac Oncol2007https://conductscience.org/library/papers/17762336PubMed
1414698542Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.Lung Cancer2004https://conductscience.org/library/papers/14698542PubMed
1516467097Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res2006https://conductscience.org/library/papers/16467097PubMed
1617387341Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.Br J Cancer2007https://conductscience.org/library/papers/17387341PubMed
1717346847Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.Lung Cancer2007https://conductscience.org/library/papers/17346847PubMed
1815205198Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial.Ann Oncol2004https://conductscience.org/library/papers/15205198PubMed
1916290256Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.Lung Cancer2006https://conductscience.org/library/papers/16290256PubMed
2017167137Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N Engl J Med2006https://conductscience.org/library/papers/17167137PubMed

See all 151 referencesDownload CSV of references

Cited by247

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 619 citations.

PMIDTitleJournalYearIn PapersSource
42876810Monoclonal antibodies associated IgA nephropathy or other nephropathies.Front Pharmacol2026https://conductscience.org/library/papers/42876810PubMed
42812841Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non-Small Cell Lung Cancer: A Multicenter Real-World Study.MedComm (2020)2026https://conductscience.org/library/papers/42812841PubMed
42638942
Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial.
Risk Manag Healthc Policy2026https://conductscience.org/library/papers/42638942PubMed
41635837Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation.Front Immunol2025https://conductscience.org/library/papers/41635837PubMed
41008962Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.Antioxidants (Basel)2025https://conductscience.org/library/papers/41008962PubMed
39791613Comparing Quality of Life and Psychological Changes in Benign and Malignant Lung Resections.Healthcare (Basel)2024https://conductscience.org/library/papers/39791613PubMed
39717667Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.JTO Clin Res Rep2025https://conductscience.org/library/papers/39717667PubMed
39461775Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial.ESMO Open2024https://conductscience.org/library/papers/39461775PubMed
39233826Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report.Oncol Lett2024https://conductscience.org/library/papers/39233826PubMed
39109434Anti-proliferation evaluation of new derivatives of indole-6-carboxylate ester as receptor tyrosine kinase inhibitors.Future Med Chem2024https://conductscience.org/library/papers/39109434PubMed
38880928[Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review].Zhongguo Fei Ai Za Zhi2024https://conductscience.org/library/papers/38880928PubMed
38505696The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.Int J Clin Pract2024https://conductscience.org/library/papers/38505696PubMed
37513950Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/37513950PubMed
37462807Role of GSDM family members in airway epithelial cells of lung diseases: a systematic and comprehensive transcriptomic analysis.Cell Biol Toxicol2023https://conductscience.org/library/papers/37462807PubMed
37031207PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration.Cell Death Dis2023https://conductscience.org/library/papers/37031207PubMed
35813717EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors.J Thorac Dis2022https://conductscience.org/library/papers/35813717PubMed
35734411Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.Front Pharmacol2022https://conductscience.org/library/papers/35734411PubMed
35681639Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer.Cancers (Basel)2022https://conductscience.org/library/papers/35681639PubMed
35619899Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies.Front Oncol2022https://conductscience.org/library/papers/35619899PubMed
35329953Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.J Clin Med2022https://conductscience.org/library/papers/35329953PubMed

See all 247 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19917871

GET https://conductscience.org/api/papers/v1/19917871/references?page=2